Preview Mode Links will not work in preview mode

trialsitenews's podcast

Oct 14, 2020

Mark Erlander, Chief Executive Officer at #CardiffOncology, Inc. talks #KRAS mutations in cancer, and existing products like mCRC, mCRPc and AML, along with three clinical programs including Zytiga-Resistant Metastatic Castration Resistant Prostate cancer (mCRPC); KRAS mutated Metastatic Colorectal #Cancer (mCRC) and Relapsed/Refractory Acute Myeloid Leukemia (AML). You can find out more here